AbCellera Biologics Inc. (ABCL) Operating income 2019–2025
AbCellera Biologics Inc. (ABCL) annual operating income history from SEC filings — each fiscal year as reported.
-$217.1MFY2025 · since FY2019: -$4.1M → -$217.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$217.1M | +31.0% |
| FY2024 | -$314.8M | -32.7% |
| FY2023 | -$237.2M | -209.6% |
| FY2022 | $216.5M | +5.9% |
| FY2021 | $204.4M | +31.0% |
| FY2020 | $156.0M | +3889.9% |
| FY2019 | -$4.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ABCL financial trends
ABCL RevenueABCL Net incomeABCL Net marginABCL Gross profitABCL Gross marginABCL Operating marginABCL Operating cash flowABCL Free cash flowABCL Capital expendituresABCL Return on equityABCL Stock buybacksABCL Dividends paidABCL Total assetsABCL Total liabilitiesABCL Shareholders’ equityABCL overview →